351 related articles for article (PubMed ID: 27662339)
1. Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Kropp LM; De Los Santos JF; McKee SB; Conry RM
J Immunother; 2016; 39(9):373-378. PubMed ID: 27662339
[TBL] [Abstract][Full Text] [Related]
2. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
3. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
5. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.
Koller KM; Mackley HB; Liu J; Wagner H; Talamo G; Schell TD; Pameijer C; Neves RI; Anderson B; Kokolus KM; Mallon CA; Drabick JJ
Cancer Biol Ther; 2017 Jan; 18(1):36-42. PubMed ID: 27905824
[TBL] [Abstract][Full Text] [Related]
6. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
Day F; Kumar M; Fenton L; Gedye C
J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
[TBL] [Abstract][Full Text] [Related]
7. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
Zecchini JM; Kim S; Yum K; Friedlander P
J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
[TBL] [Abstract][Full Text] [Related]
10. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
11. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
12. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; Prat A; Arance A
Future Oncol; 2016 Dec; 12(23):2683-2688. PubMed ID: 27581765
[TBL] [Abstract][Full Text] [Related]
15. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases.
Robin TP; Breeze RE; Smith DE; Rusthoven CG; Lewis KD; Gonzalez R; Brill A; Saiki R; Stuhr K; Gaspar LE; Karam SD; Raben D; Kavanagh BD; Nath SK; Liu AK
J Neurooncol; 2018 Oct; 140(1):55-62. PubMed ID: 29909499
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C; Chaput-Gras N; Lanoy E; Larive A; Mateus C; Routier E; Sun R; Tao YG; Massard C; Bahleda R; Schwob D; Ibrahim N; Khoury Abboud RM; Caramella C; Lancia A; Cassard L; Roy S; Soria JC; Robert C; Deutsch E
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
